TY - JOUR
T1 - Miscellaneous Indications in Bone Scintigraphy
T2 - Metabolic Bone Diseases and Malignant Bone Tumors
AU - Cook, G. J. R.
AU - Gnanasegaran, G.
AU - Chua, S.
N1 - M1 - 1
Cook, Gary J. R. Gnanasegaran, Gopinath Chua, Sue
PY - 2010/1
Y1 - 2010/1
N2 - The diphosphonate bone scan is ideally suited to assess many global, focal or multifocal metabolic bone disorders and there remains a role for conventional bone scintigraphy in metabolic bone disorders at diagnosis, investigation of complications, and treatment response assessment. In contrast, the role of bone scintigraphy in the evaluation of primary malignant bone tumors has reduced with the improvement of morphologic imaging, such as computed tomography and magnetic resonance imaging. However, an increasing role for (18)F-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography is emerging as a functional assessment at diagnosis, staging, and neoadjuvant treatment response assessment.
AB - The diphosphonate bone scan is ideally suited to assess many global, focal or multifocal metabolic bone disorders and there remains a role for conventional bone scintigraphy in metabolic bone disorders at diagnosis, investigation of complications, and treatment response assessment. In contrast, the role of bone scintigraphy in the evaluation of primary malignant bone tumors has reduced with the improvement of morphologic imaging, such as computed tomography and magnetic resonance imaging. However, an increasing role for (18)F-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography is emerging as a functional assessment at diagnosis, staging, and neoadjuvant treatment response assessment.
U2 - 10.1053/j.semnuclmed.2009.08.002
DO - 10.1053/j.semnuclmed.2009.08.002
M3 - Article
SN - 0001-2998
VL - 40
SP - 52
EP - 61
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 1
ER -